Usa Compression Partners LP (USAC) Shareholder Riverstone Holdings Has Upped Its Stake by $2.47 Million as Valuation Rose; As Concert Pharmaceuticals (CNCE) Market Value Declined, Senzar Asset Management Has Decreased Position

May 24, 2018 - By reb123z

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Logo

Senzar Asset Management Llc decreased its stake in Concert Pharmaceuticals Inc (CNCE) by 17.62% based on its latest 2017Q4 regulatory filing with the SEC. Senzar Asset Management Llc sold 59,100 shares as the company’s stock declined 14.38% with the market. The hedge fund held 276,345 shares of the health care company at the end of 2017Q4, valued at $7.15 million, down from 335,445 at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Concert Pharmaceuticals Inc for a number of months, seems to be less bullish one the $472.83M market cap company. The stock decreased 0.88% or $0.18 during the last trading session, reaching $20.21. About 81,508 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since May 24, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Riverstone Holdings Llc increased its stake in Usa Compression Partners Lp (USAC) by 0.64% based on its latest 2017Q4 regulatory filing with the SEC. Riverstone Holdings Llc bought 154,524 shares as the company’s stock rose 1.15% while stock markets declined. The hedge fund held 24.48M shares of the public utilities company at the end of 2017Q4, valued at $404.93 million, up from 24.33M at the end of the previous reported quarter. Riverstone Holdings Llc who had been investing in Usa Compression Partners Lp for a number of months, seems to be bullish on the $1.66B market cap company. The stock increased 0.11% or $0.02 during the last trading session, reaching $18.26. About 156,623 shares traded. USA Compression Partners, LP (NYSE:USAC) has risen 2.63% since May 24, 2017 and is uptrending. It has underperformed by 8.92% the S&P500.

Senzar Asset Management Llc, which manages about $442.00M and $391.71 million US Long portfolio, upped its stake in Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) by 941,800 shares to 1.45 million shares, valued at $21.72M in 2017Q4, according to the filing. It also increased its holding in Endologix Inc (NASDAQ:ELGX) by 1.29 million shares in the quarter, for a total of 2.20 million shares, and has risen its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on August, 14. They expect $-0.62 earnings per share, down 6.90% or $0.04 from last year’s $-0.58 per share. After $-0.19 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 226.32% negative EPS growth.

Investors sentiment increased to 2.62 in Q4 2017. Its up 1.44, from 1.18 in 2017Q3. It is positive, as 10 investors sold CNCE shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Quantbot Technologies Lp has 6,608 shares. Illinois-based Northern Tru Corporation has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Great Point Lc accumulated 669,472 shares. 15,625 were accumulated by Aureus Asset Management Ltd Liability. Dupont Cap Mngmt Corporation reported 37,494 shares stake. Mufg Americas Holdg Corporation accumulated 0% or 69 shares. Moreover, Prudential has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 51,443 shares. Federated Pa accumulated 21,923 shares or 0% of the stock. Strs Ohio reported 28,000 shares. Ingalls & Snyder Lc invested 1.57% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Arrowstreet Cap Partnership invested in 108,700 shares. Cubist Systematic Strategies Ltd Com holds 0.03% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 18,324 shares. Connor Clark & Lunn Investment Ltd invested 0.02% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Metropolitan Life Insurance reported 6,348 shares stake. The New York-based Blackrock has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

More news for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) were recently published by: Seekingalpha.com, which released: “Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis” on April 30, 2018. Seekingalpha.com‘s article titled: “Concert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair loss” and published on April 25, 2018 is yet another important article.

Since January 16, 2018, it had 0 insider purchases, and 6 insider sales for $2.60 million activity. ALDRICH RICHARD had sold 30,000 shares worth $590,500 on Monday, January 22.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 25 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Monday, November 6 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, November 10. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. Mizuho upgraded it to “Buy” rating and $27.0 target in Friday, March 9 report. The rating was maintained by H.C. Wainwright on Friday, October 20 with “Buy”. Stifel Nicolaus maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Friday, January 12 with “Buy” rating. The company was maintained on Monday, September 18 by H.C. Wainwright. On Friday, May 4 the stock rating was maintained by H.C. Wainwright with “Buy”. Roth Capital maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, September 22 with “Buy” rating. The stock has “Buy” rating by UBS on Tuesday, December 19.

More notable recent USA Compression Partners, LP (NYSE:USAC) news were published by: Seekingalpha.com which released: “USA Compression Partners’ (USAC) CEO Eric Long on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018, also Globenewswire.com with their article: “Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett …” published on May 01, 2018, Newsok.com published: “Energy Transfer Equity Reports First Quarter Results” on May 09, 2018. More interesting news about USA Compression Partners, LP (NYSE:USAC) were released by: Newsok.com and their article: “Delaware Court Rules in Favor of Energy Transfer on Convertible Preferred Units Issuance” published on May 17, 2018 as well as Streetinsider.com‘s news article titled: “USA Compression Partners (USAC) Misses Q1 EPS by 34c” with publication date: May 09, 2018.

Among 8 analysts covering USA Compression Partners LP (NYSE:USAC), 4 have Buy rating, 2 Sell and 2 Hold. Therefore 50% are positive. USA Compression Partners LP had 30 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, January 17. On Friday, September 9 the stock rating was initiated by FBR Capital with “Outperform”. The rating was maintained by Janney Capital on Wednesday, April 18 with “Buy”. B. Riley & Co maintained USA Compression Partners, LP (NYSE:USAC) rating on Tuesday, December 19. B. Riley & Co has “Neutral” rating and $18 target. Goldman Sachs maintained it with “Neutral” rating and $10 target in Thursday, May 12 report. FBR Capital upgraded USA Compression Partners, LP (NYSE:USAC) on Wednesday, January 17 to “Buy” rating. The firm earned “Sell” rating on Tuesday, June 21 by Goldman Sachs. The stock of USA Compression Partners, LP (NYSE:USAC) has “Neutral” rating given on Friday, September 1 by Janney Capital. The company was maintained on Wednesday, August 23 by RBC Capital Markets. On Friday, November 6 the stock rating was maintained by RBC Capital Markets with “Outperform”.

USA Compression Partners, LP (NYSE:USAC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 reb123z

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: